Condition

Esophageal Adenocarcinoma clinical trials and research

• 45Clinical trials
• 22NIH research projects
• 21Countries

Newest Esophageal Adenocarcinoma clinical trials

All recruiting trials (45)

• Adding 2141-V11 to standard therapy for advanced esophageal, gastric, or gastroesophageal junction cancer

  This study tests whether adding the drug 2141-V11 to standard anti-PD-1 therapy (with or without 5-FU) is safe for adults with advanced or metastatic esophageal, gastric, or gastroesophageal junction adenocarcinoma.

  Recruiting at 7 sites Phase 1/2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07818018

• Clonal Hematopoiesis Effects with Chemo and Radiation in Solid Cancers

  This study tests whether clonal hematopoiesis affects outcomes for adults with solid cancers who are receiving chemotherapy or radiation.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07675967

• Testing ctDNA to detect minimal residual disease in GI cancers

  This study tests whether circulating tumor DNA can reveal minimal residual disease or early relapse in patients with esophageal, gastric, or pancreatic cancer who are receiving neoadjuvant or perioperative treatment.

  Recruiting Masaryk Memorial Cancer Institute · Brno · NCT07660627

• Upfront Chemoradiation With Consolidation Chemotherapy for Localized Esophageal Adenocarcinoma

  This study tests adding consolidative chemotherapy after chemoradiation to see if it better controls the cancer for people with localized esophageal adenocarcinoma who are candidates for chemoradiation.

  Recruiting Phase 2 Duke University · Durham, North Carolina · NCT07603375

• DISP-10 for advanced colorectal, gastric, and esophageal cancers

  This trial will test a one-time combination of an engineered adenovirus (DV-10) and BCMA-directed CAR T cells (ide-cel) in adults with advanced colorectal, gastric, or esophageal cancers.

  Recruiting at 6 sites Phase 1 Dispatch Biotherapeutics · Duarte, California and 6 other locations · NCT07544589

• Givastomig with nivolumab and chemotherapy for CLDN18.2-positive metastatic stomach or gastroesophageal junction cancer

  This study will see if adding givastomig to nivolumab plus standard chemotherapy helps adults with CLDN18.2- and PD-L1-positive metastatic stomach or gastroesophageal junction cancer live longer without their disease getting worse.

  Recruiting at 5 sites Phase 2 I-Mab Biopharma US Limited · Goodyear, Arizona and 5 other locations · NCT07432295

• PF-08634404 plus chemotherapy for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma

  This trial will test whether adding the experimental medicine PF-08634404 to chemotherapy helps adults with newly diagnosed, locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma compared with nivolumab plus chemotherapy.

  Recruiting at 90 sites Phase 2/3 Pfizer · Atascadero, California and 101 other locations · NCT07392892

• Chemotherapy plus adaptive MR-guided radiotherapy for esophageal adenocarcinoma

  This Phase 1 trial will see if adding adaptive MR-guided radiotherapy to perioperative chemotherapy (FLOT) before surgery helps adults with resectable esophageal or gastroesophageal junction adenocarcinoma.

  Recruiting Phase 1 UMC Utrecht · Utrecht, Utrecht · NCT07359443

• Postoperative Low Oxygen and Chance of Leaks After Esophageal Surgery

  This study looks at whether low oxygen levels after esophageal cancer surgery increase the chance of an anastomotic leak.

  Recruiting at 6 sites Sun Yat-sen University · Guangzhou, Guangdong and 5 other locations · NCT07309991

• PLX-61639 for advanced SMARCA4-deficient solid tumors

  This trial will test a daily oral drug called PLX-61639 in people with advanced or metastatic solid tumors that have a SMARCA4 loss and who have no other approved treatment options.

  Recruiting at 10 sites Phase 1 Plexium, Inc. · Scottsdale, Arizona and 9 other locations · NCT07284186

• Planned surgery or focused local treatment after chemo for metastatic upper-GI adenocarcinoma with undetectable ctDNA

  This test sees if adding planned surgery or local treatments after three months of chemotherapy helps people with metastatic upper-gastrointestinal adenocarcinomas who have undetectable ctDNA.

  Recruiting Phase 2 Yale University · New Haven, Connecticut · NCT07282912

• Subcutaneous versus intravenous immune therapy: which do patients prefer?

  This project will test whether patients with advanced cancers prefer subcutaneous (under‑the‑skin) versus intravenous nivolumab or, if available, pembrolizumab.

  Recruiting Phase 2 University of Pittsburgh · Pittsburgh, Pennsylvania · NCT07223424

• Liquid nitrogen spray cryotherapy before chemotherapy for locally advanced esophageal cancer

  This study tests whether adding liquid nitrogen spray cryotherapy to standard chemotherapy helps people with locally advanced esophageal adenocarcinoma reach better treatment response than chemotherapy alone.

  Recruiting Phase 2 Case Comprehensive Cancer Center · Weston, Florida · NCT07222657

• NRM-823 for advanced or metastatic refractory solid tumors

  This trial tests whether NRM-823 is safe and can help people with advanced or metastatic head and neck, esophageal, gastric, or related cancers.

  Recruiting at 18 sites Phase 1 Normunity AccelCo, Inc. · Denver, Colorado and 17 other locations · NCT07182149

• Single chest drain versus two drains after esophagectomy

  This will test whether using one chest drain instead of two helps people recover more easily after open surgery to remove esophageal cancer.

  Recruiting Khyber Teaching Hospital · Peshawar, Khyberpukhtunkhwa · NCT07125248

• PF-08046876 for people with advanced solid tumors

  This trial tests a new antibody–drug conjugate called PF-08046876 given by IV in adults with advanced bladder, lung, head and neck, esophageal, or pancreatic cancers to see if it is safe and how it affects tumors.

  Recruiting at 30 sites Phase 1 Pfizer · Duarte, California and 30 other locations · NCT07090499

• Tislelizumab plus FLOT given before surgery for operable esophagus or stomach adenocarcinoma

  This trial tests whether adding the immunotherapy drug tislelizumab to FLOT chemotherapy given before surgery helps people with locally advanced, resectable esophagus or stomach adenocarcinoma shrink tumors and better tolerate treatment.

  Recruiting at 2 sites Phase 1 Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Frankfurt and 3 other locations · NCT07059299

• IntraTumor T-Cell Boost with Dual Immune Checkpoint Inhibitors in ARID1A-Mutated Esophageal/Gastric Adenocarcinoma

  A first-in-human test of a single-dose combination of tremelimumab and durvalumab in adults with ARID1A-mutated, non-metastatic esophageal, GEJ, or stomach adenocarcinoma to see if it can increase tumor T cells.

  Recruiting Early Phase 1 University of California, Irvine · Orange, California · NCT06824363

• Itraconazole with endoscopic ablation to prevent esophageal cancer in high‑risk Barrett's esophagus

  This study tests if adding itraconazole to the standard endoscopic ablation can better prevent esophageal cancer in people with high-risk Barrett's esophagus.

  Recruiting at 4 sites Phase 2 National Cancer Institute (NCI) · Kansas City, Kansas and 5 other locations · NCT06732388

• Detecting Barrett's Esophagus in Patients Without GERD Symptoms

  This study is testing a new way to find Barrett's esophagus in people who don’t have GERD symptoms by using a simple capsule test instead of the usual endoscopy.

  Recruiting at 5 sites Case Comprehensive Cancer Center · Aurora, Colorado and 4 other locations · NCT06687603

• Mesothelin-targeted CAR T-cell therapy for esophagogastric cancer

  This study is testing a new treatment that uses modified immune cells to target and attack tumors in people with advanced esophagogastric cancer.

  Recruiting at 7 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT06623396

• Assessing Barrett's Esophagus in Patients with Anorexia Nervosa and Purging Behaviors

  This study is trying to see if people with anorexia nervosa who purge have Barrett's esophagus, using non-invasive tests to check for this condition in patients aged 18-65.

  Recruiting at 3 sites Denver Health and Hospital Authority · Denver, Colorado and 2 other locations · NCT06532734

• Using tissue, brush, and blood tests to improve cancer risk prediction and quality of life tracking in Barrett's Esophagus

  This will try extra biopsies, esophageal brushings, blood tests, and short questionnaires to see if they can better predict cancer risk and track quality of life for adults with Barrett's Esophagus who are being evaluated for possible early cancer.

  Recruiting at 9 sites University Hospital, Antwerp · Edegem, Antwerpen and 8 other locations · NCT06523374

• Combination of OBP-301 and Pembrolizumab for Advanced Esophagogastric Cancer

  This study is trying a new treatment combining OBP-301 and pembrolizumab to see if it can help people with advanced esophageal and gastric cancer who haven't responded well to previous immunotherapy.

  Recruiting at 2 sites Phase 2 Weill Medical College of Cornell University · New York, New York and 1 other locations · NCT06340711

• Finding the right dose of zongertinib for HER2+ cancer treatment

  This study is testing the best dose of zongertinib to see if it can help adults with hard-to-treat HER2+ cancers shrink their tumors.

  Recruiting at 98 sites Phase 1/2 Boehringer Ingelheim · Cerritos, California and 103 other locations · NCT06324357

• Using a swallowable sponge to collect esophageal samples for Barrett's esophagus detection

  This study is testing a swallowable sponge to see if it can safely collect samples from the esophagus to help detect Barrett's esophagus and esophageal cancer in patients who may have these conditions.

  Recruiting at 3 sites Mayo Clinic · Scottsdale, Arizona and 4 other locations · NCT06071845

• Experimental treatment for advanced solid tumors using AZD5863

  This study is testing a new treatment called AZD5863 to see if it can help adults with advanced solid tumors that have a specific marker in their cancer cells.

  Recruiting at 24 sites Phase 1/2 AstraZeneca · Jacksonville, Florida and 24 other locations · NCT06005493

• Registry for patients undergoing esophageal cancer screening

  This study is collecting information from patients getting screened for Barrett Esophagus and Esophageal Adenocarcinoma using a new test to see how well it works and how patients feel about the process.

  Recruiting PAVmed Inc. · Lake Forest, California · NCT05965999

• Comparing surveillance and therapy for Barrett's esophagus with low-grade dysplasia

  This study is testing whether regular check-ups or a treatment to remove precancerous cells is better for people with Barrett's esophagus and low-grade dysplasia.

  Recruiting at 28 sites University of Colorado, Denver · Birmingham, Alabama and 29 other locations · NCT05753748

• Oral bevacizumab-800CW and cetuximab-800CW to detect early esophageal adenocarcinoma

  This trial tests whether drinking two fluorescent tracers before an endoscopy helps doctors find early esophageal adenocarcinoma in people with Barrett's esophagus or suspected dysplasia.

  Recruiting Phase 2 University Medical Center Groningen · Groningen, Provincie Groningen · NCT05745857

• Comparing biopsy methods for monitoring Barrett's Esophagus

  This study is testing whether a new biopsy method called WATS is better than the usual random biopsies for monitoring patients with Barrett's Esophagus who are at high risk for serious complications.

  Recruiting Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Amsterdam, North Holland · NCT05642338

• Evaluating Itraconazole for Treating Esophageal Cancer

  This study is testing if adding the antifungal medication itraconazole to standard treatment can help improve outcomes for patients with operable esophageal cancer.

  Recruiting at 7 sites Phase 2 VA Office of Research and Development · Palo Alto, California and 6 other locations · NCT05563766

• Comparing two methods for sampling Barrett's esophagus

  This study is testing which method, the standard biopsy or a new sampling technique, is better at finding early signs of cancer in people with Barrett's esophagus.

  Recruiting at 14 sites University of Colorado, Denver · Gilbert, Arizona and 13 other locations · NCT05530343

• Using trastuzumab and pertuzumab to improve survival in HER2+ esophageal cancer

  This study is testing if adding two targeted therapies, trastuzumab and pertuzumab, to standard treatment can help people with HER2-positive esophageal cancer live longer.

  Recruiting Phase 3 Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Amsterdam · NCT05188313

• Combining chemotherapy and immunotherapy for advanced esophagogastric cancer

  This study is testing a new treatment plan that combines two chemotherapy drugs with an immunotherapy to see if it helps people with advanced esophagogastric cancer feel better and live longer.

  Recruiting at 5 sites Phase 2 Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Amsterdam and 7 other locations · NCT05177133

• Using obeticholic acid to prevent progression in Barrett's esophagus

  This study is testing if the medication obeticholic acid can help prevent Barrett's esophagus from getting worse in people at risk of developing esophageal cancer.

  Recruiting at 6 sites Phase 2 National Cancer Institute (NCI) · Kansas City, Kansas and 7 other locations · NCT04939051

• Evaluating TJ033721 for advanced or metastatic solid tumors

  This study is testing a new drug called TJ033721 to see if it can help people with advanced or metastatic solid tumors, both on its own and in combination with other treatments.

  Recruiting at 7 sites Phase 1 I-Mab Biopharma US Limited · Orange, California and 20 other locations · NCT04900818

• Using propranolol with standard treatment for esophageal adenocarcinoma

  This study is testing if adding propranolol to the usual treatment for esophageal adenocarcinoma can make it safer and help patients live longer after surgery.

  Recruiting Phase 2 Roswell Park Cancer Institute · Buffalo, New York · NCT04682158

• Testing a new drug for advanced solid tumors

  This study is testing a new drug called sigvotatug vedotin to see if it can safely help people with advanced solid tumors, both on its own and with other treatments.

  Recruiting at 145 sites Phase 1 Seagen Inc. · Anchorage, Alaska and 157 other locations · NCT04389632

• Comparing robot-assisted and conventional minimally invasive surgery for esophageal cancer

  This study is testing whether robot-assisted surgery is better than traditional minimally invasive surgery for patients with esophageal cancer.

  Recruiting University Medical Center Mainz · Mainz · NCT04306458

• Registry for gastric and esophageal cancer treatments in Germany

  This study is collecting information on how patients in Germany with advanced esophageal and stomach cancers are treated to see how well different treatments work in real life.

  Recruiting iOMEDICO AG · Multiple Locations · NCT04290806

• Combination of chemotherapy and immunotherapy for advanced esophageal and gastric cancer

  This study is testing a new combination of chemotherapy and immunotherapy to see if it helps people with advanced esophageal and gastric cancer feel better and have fewer side effects than current treatments.

  Recruiting Phase 2 University of Wisconsin, Madison · Madison, Wisconsin · NCT04150640

• Combining Anti-PD-1 Therapy with Metformin and Rosiglitazone for Cancer Treatment

  This study is testing if combining a cancer treatment called anti-PD-1 therapy with two diabetes medications, Metformin and Rosiglitazone, can help people with advanced solid tumors fight their cancer better.

  Recruiting Phase 2 University of Pittsburgh · Pittsburgh, Pennsylvania · NCT04114136

• Combining cabozantinib and durvalumab for advanced gastrointestinal cancers

  This study is testing a new combination of two cancer drugs, cabozantinib and durvalumab, to see if they can help people with advanced gastrointestinal cancers feel better and improve their outcomes.

  Recruiting Phase 1/2 University of Pittsburgh · Westwood, Kansas and 1 other locations · NCT03539822

• Understanding the progression of Barrett's Esophagus and its risk factors

  This study looks at how certain factors might affect the progression of GERD and Barrett's Esophagus to see who is at higher risk for serious issues like cancer.

  Recruiting Midwest Veterans' Biomedical Research Foundation · Kansas City, Missouri · NCT00574327

NIH-funded research (22)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Natural products to block IL-8 signaling and prevent Barrett's Esophagus from turning into esophageal cancer

  A搜索-friendly plan to use safe natural compounds to interrupt a key inflammatory signal (IL-8) and stop Barrett’s esophagus from turning into esophageal cancer in people with GERD.

  NIH research Ohio State University · Columbus, UNITED STATES · NIH-11580206

• Overcoming Immunotherapy Resistance in Metastatic Gastric/Esophageal Cancer

  A Mayo Clinic-led study aims to find better combos of immune therapy and standard treatment to help people with metastatic gastric and esophageal cancer who don’t respond well to current options.

  NIH research Mayo Clinic Rochester · Rochester, United States · NIH-11448895

• NEK2's role in esophageal cancer development

  A study looking at how the NEK2 protein contributes to the development and progression of esophageal adenocarcinoma in conditions like Barrett’s esophagus.

  NIH research University of Miami School of Medicine · Coral Gables, United States · NIH-11448644

• Understanding why some esophageal cancer patients don’t respond to chemoradiation

  A research project at MD Anderson is looking at why esophageal cancer patients often don’t fully respond to chemoradiation and how tumor biology and the surrounding environment affect treatment.

  NIH research University of Tx Md Anderson Can Ctr · Houston, United States · NIH-11395551

• AI-powered screening to detect Barrett’s esophagus and early esophageal cancer

  A Mayo Clinic team is testing an AI-assisted tool that uses health data to identify people at risk for Barrett’s esophagus and early esophageal cancer so they can get timely endoscopic evaluation.

  NIH research Mayo Clinic Arizona · Scottsdale, United States · NIH-11384589

• SOX4-driven transcription in esophageal cancer

  Researchers are studying how a specific gene network drives esophageal cancer that can arise from Barrett's esophagus, aiming to uncover new targets for therapy.

  NIH research University of Miami School of Medicine · Coral Gables, United States · NIH-11362549

• Understanding how a DNA repair protein helps esophageal cancer resist treatment

  A new NIH grant is exploring how a DNA repair protein called APE1 helps esophageal cancer cells survive and resist chemotherapy in Barrett’s esophagus toward preventing or treating esophageal cancer.

  NIH research University of Miami School of Medicine · Coral Gables, United States · NIH-11362545

• Disruption of Transcription Networks in Esophageal Adenocarcinoma Tumorigenesis

  A research program at a major medical school is studying how certain gene networks and cellular processes contribute to the development of esophageal cancer in people with Barrett's esophagus and reflux.

  NIH research University of Miami School of Medicine · Coral Gables, United States · NIH-11362544

• Genetic and epigenetic predictors of esophageal cancer risk

  This project uses genetic and epigenetic information to find which people with Barrett's esophagus are most likely to develop esophageal adenocarcinoma.

  NIH research Fred Hutchinson Cancer Center · Seattle, United States · NIH-11176757

• How tumor genes and surrounding cells help esophageal cancer resist chemoradiation

  This project looks at tumor biopsies from people with esophageal adenocarcinoma getting chemoradiation to find cellular changes that let cancer survive treatment.

  NIH research University of Tx Md Anderson Can Ctr · Houston, United States · NIH-11172420

• Less-invasive molecular tests to find Barrett's esophagus and early esophageal cancer

  This project builds less-invasive molecular tests plus AI risk tools to help find Barrett's esophagus and early esophageal cancer in people with reflux or other risk factors.

  NIH research Mayo Clinic Arizona · Scottsdale, United States · NIH-11164271

• Understanding a Gene's Role in Esophageal Cancer

  This project looks for new ways to stop esophageal cancer from growing by understanding how certain cells change.

  NIH research University of Miami School of Medicine · Coral Gables, United States · NIH-11127396

• Understanding how cells in esophageal cancer resist treatment

  This work explores how certain cells in esophageal cancer become resistant to treatment and survive, especially in people with Barrett's esophagus.

  NIH research University of Miami School of Medicine · Coral Gables, United States · NIH-11127390

• Understanding Gene Activity Changes in Esophageal Cancer

  This research explores how acid reflux can lead to esophageal cancer by changing gene activity, hoping to find new ways to treat this condition.

  NIH research University of Miami School of Medicine · Coral Gables, United States · NIH-11127388

• Investigating how gut bacteria and signaling pathways affect esophageal cancer

  This study is looking at how changes in gut bacteria, especially after losing a common stomach bug called Helicobacter pylori, might be linked to the increasing cases of esophageal adenocarcinoma (a type of throat cancer), and it aims to find out how these bacteria interact with the esophagus to potentially promote can

  NIH research Columbia University Health Sciences · New York, United States · NIH-11007166

• Creating a DNA test to identify Barrett's esophagus patients at risk of cancer

  This study is working on a new DNA test to help find out which patients with Barrett's esophagus are more likely to develop esophageal cancer, so they can get the right care sooner and feel more at ease about their health.

  NIH research Pre-Cancer Diagnosis, LLC · Belle Mead, United States · NIH-10919150

• Understanding how genetic and environmental factors affect resistance to cancer treatment in esophageal adenocarcinoma

  This study is looking into why some people with esophageal adenocarcinoma don’t respond well to chemoradiation therapy, by examining their tumor samples to find out what genetic and environmental factors might be making the treatment less effective, with the hope of improving future treatment options.

  NIH research University of Tx Md Anderson Can Ctr · Houston, United States · NIH-10917384

• Understanding the genetics and risk factors for esophageal adenocarcinoma

  This study is looking at the genes and other factors that might help us understand why some people with Barrett's esophagus develop esophageal adenocarcinoma, a serious type of cancer, so we can better identify those at higher risk and improve how we monitor them without putting everyone through unnecessary tests.

  NIH research Fred Hutchinson Cancer Center · Seattle, United States · NIH-10914882

• New methods to detect Barrett’s esophagus and esophageal cancer

  This study is testing a new, gentle way to check for Barrett’s esophagus and early signs of esophageal cancer using a special sponge to collect samples, which could help catch these conditions earlier and make it easier for patients.

  NIH research Mayo Clinic Rochester · Rochester, United States · NIH-10871905

• Investigating the role of SOX4 in esophageal adenocarcinoma development

  This study is looking at how a gene called SOX4 affects the development of esophageal adenocarcinoma, a type of cancer that is becoming more common, to find new ways to treat patients who have it, especially those with Barrett's esophagus caused by long-term acid reflux.

  NIH research University of Miami School of Medicine · Coral Gables, United States · NIH-10866612

• Understanding how certain proteins affect esophageal cancer development

  This study is looking at how a protein called APE1 might play a role in the development of esophageal cancer in people with Barrett's esophagus from chronic acid reflux, and it hopes to find new ways to help treat this condition by understanding how cancer cells cope with stress and inflammation.

  NIH research University of Miami School of Medicine · Coral Gables, United States · NIH-10866610

• Understanding how certain proteins contribute to esophageal cancer development

  This study is looking into how long-term acid reflux might lead to esophageal cancer, and it's for anyone interested in understanding more about this condition and finding better treatments.

  NIH research University of Miami School of Medicine · Coral Gables, United States · NIH-10866608

Related topics

Quick answers

How many Esophageal Adenocarcinoma clinical trials are recruiting right now?

45, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 21 countries. The most sites are in United States (33 trials), China (7 trials), Netherlands (6 trials), France (5 trials), Spain (4 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 14, Phase 1: 9, Phase 1/2: 4, Early Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →